BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 15791829)

  • 21. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
    Gadducci A; Tana R; Fanucchi A; Genazzani AR
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
    Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
    Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tumor markers in gynecological and breast cancer].
    Jobo T; Sato R; Kuramoto H
    Rinsho Byori; 2003 Dec; 51(12):1188-94. PubMed ID: 14743742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Gestational trophoblast tumors--rare, but important in general practice].
    Ebeling K; Schönborn I; Johannsmeyer D
    Z Arztl Fortbild (Jena); 1994 Oct; 88(10):773-8. PubMed ID: 7529957
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical use of HCG and hCG beta determinations.
    Mann K; Saller B; Hoermann R
    Scand J Clin Lab Invest Suppl; 1993; 216():97-104. PubMed ID: 7690985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HCG and SP-1 as markers in trophoblast tumors. The HCG/SP-1 ratio].
    Than GN; Tatra G; Csaba IF; Szabo DG; Bohn H
    Gynakol Rundsch; 1988; 28(3):157-65. PubMed ID: 2844633
    [No Abstract]   [Full Text] [Related]  

  • 27. Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency.
    Schauenstein E; Lahousen M; Weblacher M; Steinschifter W; Estelberger W; Schauenstein K
    Cancer; 1996 Aug; 78(3):511-6. PubMed ID: 8697398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tumor markers and their significance in gynecologic oncology].
    Melchert F; Kreienberg R
    Gynakologe; 1980 Jun; 13(2):74-88. PubMed ID: 6299910
    [No Abstract]   [Full Text] [Related]  

  • 29. [Assessment of urinary beta-core fragment of hCG as a tumor marker of cervical cancer].
    Kinugasa M; Nishimura R; Hasegawa K; Okamura M; Kimura A; Ohtsu F; Takeuchi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):188-94. PubMed ID: 1545171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer.
    Cole LA; Sutton JM
    J Reprod Med; 2004 Jul; 49(7):545-53. PubMed ID: 15305826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of tumour markers in molar pregnancy.
    Hegab HM; Schindler AE; Rizk M; Ramadan M
    Arch Gynecol Obstet; 2003 Aug; 268(3):151-4. PubMed ID: 12942241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free beta-subunit, a reliable marker of placental site trophoblastic tumors.
    Cole LA; Khanlian SA; Muller CY; Giddings A; Kohorn E; Berkowitz R
    Gynecol Oncol; 2006 Aug; 102(2):160-4. PubMed ID: 16631918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumor markers in gynecologic malignancies].
    Tojo S; Suzuki A; Fujii S; Ashitaka Y; Maruo T; Matsuura S
    Gan No Rinsho; 1983 May; 29(6):678-83. PubMed ID: 6192268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Importance of CA-50 detection in malignant gynecologic tumors].
    Indraccolo SR; Greco A; Cartechini MG; Compagnucci P
    Minerva Ginecol; 1990 Dec; 42(12):507-9. PubMed ID: 2089292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour markers in gynaecologic oncology.
    Onsrud M
    Scand J Clin Lab Invest Suppl; 1991; 206():60-70. PubMed ID: 1719611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human chorionic gonadotropin and CA 15-3 producing adenocarcinoma.
    Uçkaya G; Ozet A; Arpaci A; Kömürcü S
    Nuklearmedizin; 1998; 37(8):297-8. PubMed ID: 9868713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pros and cons of gynecologic tumor markers.
    Bast RC; Hunter V; Knapp RC
    Cancer; 1987 Oct; 60(8 Suppl):1984-92. PubMed ID: 2443235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p16 expression in the female genital tract and its value in diagnosis.
    O'Neill CJ; McCluggage WG
    Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
    Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
    Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.